For the quarter ending 2025-09-30, DSGN had -$4,615K decrease in cash & cash equivalents over the period. -$11,162K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -16,997 | -36,798 |
| Depreciation | 155 | 311 |
| Stock-based compensation | 3,590 | 7,524 |
| Amortization of premiums on investment securities, net | 767 | 1,974 |
| Non-cash lease expense | -7 | -6 |
| Deferred financing costs | 0 | 427 |
| Prepaid expense and other assets | -459 | 955 |
| Accounts payable and other liabilities | 2,405 | 241 |
| Net cash used in operating activities | -11,162 | -31,230 |
| Purchases of investment securities | 78,075 | 126,080 |
| Proceeds from maturities of investment securities | 84,585 | 154,225 |
| Purchases of property and equipment | 0 | 159 |
| Net cash provided by investing activities | 6,510 | 27,986 |
| Issuance of common stock through employee stock purchase plan | 0 | 361 |
| Proceeds from the exercise of stock options | 37 | 23 |
| Net cash provided by financing activities | 37 | 384 |
| Net (decrease) increase in cash and cash equivalents | -4,615 | -2,860 |
| Cash and cash equivalents at beginning of period | 22,563 | - |
| Cash and cash equivalents at end of period | 15,088 | - |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)